FOOD AND DRUG ADMINISTRATION
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES
ADVISORY
COMMITTEE
Hilton Hotel
8727 Colesville Road
Silver Spring, MD 20910
AGENDA
8:00 a.m. Administrative Remarks,
William Freas, PhD, Executive Secretary
8:10 a.m. Opening Remarks
Suzette Priola, PhD, Chairperson
Introduction
Jesse L. Goodman, MD, MPH,
Director, Center for Biologics Evaluation and Research
Presentation of Plaques to Retiring Committee Members
Jesse Goodman, MD, MPH
8:20 a.m. Informational Presentation #1: USDA BSE Licensed Tests and Enhanced Surveillance Program, Lawrence Elsken, DVM, USDA
Informational Presentation #2: USDA Review of Worldwide BSE Situation and USDA Responses, Lisa Ferguson, DVM, USDA
Informational Presentation #3: Update on Animal Feed Rulemaking, Burt Pritchett, DVM, CVM
9:05 a.m. Questions for Presenters
9:15 a.m. OPEN PUBLIC HEARING
10:05 Informational Presentation #4: Labeling Claims for TSE Clearance Studies for Plasma Derivative Products,
Dorothy Scott, MD, OBRR, FDA
10:15 Informational Presentation # 5: Industry-Wide Data on TSE Clearance from Plasma Products, Henry Baron, MD, Senior Director- Prion Research, ZLB Behring (Speaking on behalf of the Plasma Protein Therapeutics Association)
10:30 BREAK
TSEAC AGENDA (page 2)
10:50 a.m. Topic – Presumptive Transfusion Transmissions of Variant CJD (vCJD): Consideration of Current FDA-Recommended Safeguards
A. FDA Introduction, David Asher, MD, OBRR/FDA
B. Presumptive Transfusion Transmission of vCJD (review of CJD and vCJD: UK and EU epidemiology, case reports, surveillance and projections, potential public health implications, and responses), Professor Robert G. Will, MD, UK CJD Surveillance Unit
C. Comparison of the Transfusion Risk for CJD vs. vCJD, Steven Anderson, PhD, OBE/FDA
D. Leukoreduction and Its Failure to Remove Most Infectivity from Blood, Luisa Gregori, PhD, VA Medical Center
12:10 p.m. Questions for Speakers
12:25 LUNCH
1:25 E. Changes in Canadian CJD/vCJD Blood Safety Policies,
Peter Ganz, PhD, HealthCanada
F. Current Safeguards for Blood Products Recommended by FDA, Dorothy Scott, MD, OBRR/CBER
G. Possible Effects of Prior CJD-Related Blood Donor Deferrals on Blood Supply, Alan Williams, PhD, OBRR/CBER
2:30 Questions for Speakers
2:45 OPEN PUBLIC HEARING
3:15 BREAK
3:35 Questions to the Committee
3:45 Committee Discussion and Vote
5:00 p.m. ADJOURN